Logo Prima Biomed


Welcome to the Newsroom

20 October 2017

Dr. Frédéric Triebel presenting at the World Immunotherapy Congress 2017


SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”) announces that Dr. Frédéric Triebel, Prima’s Chief Scientific Officer & Medical Officer, will be giving an oral presentation on Prima’s ongoing TACTI-mel Phase 1 clinical trial in metastatic melanoma at the World Immunotherapy Congress 2017 in Basel, Switzerland at 5.50pm CEST on October 31, 2017.

(...)